Stelara (ustekinumab) / J&J, Tanabe Pharma, BMS - LARVOL DELTA

Efficacy and safety of dual-targeted therapy in children with inflammatory bowel disease: Retrospective cohort study. (PubMed, World J Clin Pediatr) - "A DTT may be considered for children with refractory IBD. This strategy was shown to be most effective among children with a very early onset of the disease."

Journal • Retrospective data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Quantification of visceral adipose tissue volume predicts both short-term and long-term transmural healing in patients with Crohn's disease receiving Ustekinumab. (PubMed, Ther Adv Gastroenterol) - "Our study demonstrated that baseline VAT was an independent risk factor for predicting both short- and long-term TH in CD patients receiving UST. Patients with lower VAT volume at baseline were more likely to achieve TH after UST treatment."

Journal • Crohn's disease • Gastroenterology • Immunology • Inflammation • Inflammatory Bowel Disease • CRP

IGA NEPHROPATHY FOLLOWING RISANKIZUMAB THERAPY FOR PSORIATIC ARTHRITIS: A CASE REPORT (ISN-WCN 2026) - "He was diagnosed with psoriatic arthritis in 2018 and treated sequentially with brodalumab, adalimumab, and ixekizumab, but these agents failed to adequately control his symptoms. While IgAN has been reported in association with the IL-12/23p40 inhibitor ustekinumab, no previous case of risankizumab-associated IgAN has been described. Further accumulation of biologic-associated IgAN cases, including those involving IL-23p19 inhibition, may help elucidate the underlying disease mechanisms."

Case report • Clinical • Crohn's disease • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Glomerulonephritis • IgA Nephropathy • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Psoriasis • Psoriatic Arthritis • Renal Disease • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL12A • IL23A • IL4

Outcomes of Risankizumab in Patients with Crohn's Disease and Prior Ustekinumab Exposure in a Multicenter Academic Institution. (PubMed, Dig Dis Sci) - "RZB appears to be an effective treatment option for patients with CD and prior UST use, particularly those with secondary loss of response. A higher number of previously trialed therapies was associated with reduced likelihood of response, underscoring the importance of early, strategic treatment sequencing."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • CRP

Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID. (PubMed, United European Gastroenterol J) - "In UC patients failing vedolizumab, second-line IFX, anti-TNF SC, and ustekinumab showed similar effectiveness and persistence. Infliximab remains a robust option for rapid control in high inflammatory burden, whereas ustekinumab may be preferred for its superior safety profile in high-risk patients."

Journal • Retrospective data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative. (PubMed, Clin Pharmacol Ther) - "FDA used an active-comparator new-user cohort design, data from six Sentinel Data Partners, a method developed in Sentinel for identifying serious infection, and ARIA analytic tools to estimate serious infection incidence in adult CD patients during treatment with ustekinumab or an active comparator (infliximab, adalimumab, or vedolizumab). In conclusion, IPTW analyses excluded large magnitude risks from ustekinumab for serious infection. This report describes the first ARIA study to use complex confounding adjustment to help resolve a safety issue identified during FDA review of a marketing application."

Journal • P4 data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Novel Coronavirus Disease

Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis. (PubMed, J Crohns Colitis) - "Advanced IBD therapies demonstrate an overall favorable safety profile. Active disease, older maternal age, and longer disease duration were significant predictors of complications. Associations with third-trimester exposure do not support routine discontinuation, as this likely reflects underlying disease severity rather than treatment effect, reinforcing the priority of maintaining remission during pregnancy."

Clinical • Journal • Retrospective data • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Analysis of possible baseline and treatment-course factors associated with non-remission in patients with Crohn's disease treated with ustekinumab: a retrospective real-life analysis. (PubMed, Pharmacol Rep) - No abstract available

Journal • Retrospective data • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

Real-Life Use of Subcutaneous Biologicals and JAK Inhibitors in IBD Maintenance Therapy: Treatment Continuation, Switching Patterns, and Concomitant Medications. (PubMed, Clin Exp Gastroenterol) - "At 24 months, treatment continuation rates were 51-57% for adalimumab, golimumab, ustekinumab and tofacitinib (in UC); and 71-80% for infliximab, vedolizumab and ustekinumab (in CD). Most switches involved a different mode-of-action. While conventional medications were tapered, IS and 5-ASA may support treatment continuation."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Successful and Risk-Minimizing Treatment of Ulcerative Colitis by Positive Switch from JAK Inhibitors to Ustekinumab. (PubMed, Biologics) - "Case 1: A 53-year-old man with steroid-dependent UC achieved rapid symptomatic improvement and complete mucosal healing on upadacitinib...Case 2: A 36-year-old woman with refractory UC achieved clinical remission and mucosal healing with filgotinib following inadequate response to vedolizumab and corticosteroids...These cases suggest that a positive switch may be a reasonable option for patients who respond to JAK inhibitors but have concerns about long-term safety. Additional cases are required to better define the clinical role of this strategy."

Journal • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Bowel Disease • Respiratory Diseases • Thrombosis • Ulcerative Colitis • Varicella Zoster

A Prospective Observational Study on the Efficacy and Safety of Guselkumab in the Treatment of Crohn's Disease Patients Previously Treated With Ustekinumab (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New trial • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Challenges in managing primary toxoplasmosis in a patient with Behçet's disease receiving ustekinumab and apremilast and allergic to trimethoprim/sulfamethoxazole (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Rare Diseases

Chlamydia psittaci pneumonia in a patient using ustekinumab therapy for Crohn's disease. (PubMed, ASM Case Rep) - "Targeted treatment with doxycycline led to clinical recovery. It underscores the importance of exposure history and considering atypical pathogens in immunocompromised patients. Clinicians should maintain vigilance for opportunistic infections in individuals receiving targeted biologic therapies."

Journal • Cardiovascular • Crohn's disease • Gastroenterology • Immunology • Infectious Disease • Inflammatory Bowel Disease • Pneumonia • Pulmonary Embolism • Respiratory Diseases • IL12A

A nationwide cohort study of depression outcomes among persons with psoriasis treated with biologics (AAD 2026) - "Methods This new-user cohort study used US claims data (March2017-June 2023) to identify persons with psoriasis initiating IL-17i, IL-23i, ustekinumab and TNFi...Conclusions In this real-world cohort study of patients with psoriasis treated with biologics, there was no significant difference in the risk of depression outcomes between the drug groups studied among those with and without prior depression. Self-harm events were rare."

CNS Disorders • Depression • Dermatology • Immunology • Mood Disorders • Psoriasis • Psychiatry • Suicidal Ideation

Real-World Comparative Risk of Infections with Biologic Therapy in Pediatric Psoriasis: A Nationwide Cohort Study (AAD 2026) - "Methods This new-user cohort study used US claims data (December 2016-June 2023) to identify children aged 6 to 17 years with psoriasis and compared the risk of inpatient infections and outpatient infections requiring antimicrobial treatment in those initiating etanercept, ustekinumab, and interleukin -17 inhibitors (IL-17i: secukinumab or ixekizumab). Conclusions In this real-world cohort study among children with psoriasis treated with biologics, the risk of outpatient infections requiring treatment was similar between initiators of IL-17i, etanercept and ustekinumab. No serious inpatient infections were observed."

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Infectious Disease • Pediatrics • Psoriasis

Efficacy of Biologics and Small Molecules for Pediatric Plaque Psoriasis: A Systematic Review of Randomized Control Trials (AAD 2026) - "Systemic therapies evaluated were apremilast (22.1%, 163/738), etanercept (19.9%, 147/738), secukinumab (16.5%, 122/738), ixekizumab (15.6%, 115/738), adalimumab (10.4%, 77/738), ustekinumab (9.9%, 73/738), and guselkumab (5.6%, 41/738). No treatment-related deaths were reported. Our results indicate that interleukin-17 inhibitors, particularly secukinumab and ixekizumab, achieve the highest efficacy in pediatric plaque psoriasis with favorable short-term safety profiles."

Clinical • Review • Dermatology • Immunology • Infectious Disease • Inflammation • Pediatrics • Psoriasis • IL17A

Specialty Pharmacy Interventions in Plaque Psoriasis and Psoriatic Arthritis: A 4-Year Institutional Review (AAD 2026) - "We identified n=911 with plaque psoriasis and/or psoriatic arthritis, with the five most prescribed systemics being: risankizumab-rzaa(RIS)=28.2%, apremilast(APR)=22.7%, secukinumab(SEC)=13.1%, ustekinumab(UST)=11.6%, ixekizumab(IXE)=11.3%. While RIS was the most prescribed medication, APR had the most interventions in each category, most notably interventions related to side-effects, drug-drug interactions, medication discontinuation, or adjunctive medications or healthcare visits required to address an issue. This study also highlights the benefits of an academic SP to improve patient care and medication management."

Clinical • Review • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Comparative Outcomes of Immunomodulatory Versus Conventional Therapies in Congenital Ichthyosis: A TriNetX Cohort Study (AAD 2026) - "Patients were divided into two cohorts: an immunomodulatory group (n=1,364) including dupilumab, azathioprine, ustekinumab, ixekizumab, infliximab, adalimumab, secukinumab, cyclosporine, and JAK inhibitors and a conventional therapy group (n=1,364) including keratolytics, isotretinoin, acretin, adapalene, etretinate, adapalene, and tretinoin. Immunomodulatory therapies, particularly biologics, were associated with a reduced burden of inflammatory comorbidities, suggesting potential improvements in disease control and quality of life. Larger studies are warranted to delineate the long-term effectiveness of specific biologics in this population."

Immunomodulating • Acne Vulgaris • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Vitiligo

Cutaneous Crohn’s Disease: A Systematic Review of Epidemiology, Clinical Manifestations, Diagnosis, and Treatment (AAD 2026) - "Ustekinumab was effective in anti-TNF–refractory disease, while risankizumab and upadacitinib showed complete clearance in isolated reports. Conventional agents (azathioprine, corticosteroids) offered only partial, often transient, benefit... CCD remains underrecognized and frequently misdiagnosed. Early biopsy and multidisciplinary evaluation are essential. While anti-TNF therapy remains standard, emerging IL-23 and JAK inhibitors represent promising options."

Clinical • Review • Crohn's disease • Dermatitis • Dermatopathology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Psoriasis • IL23A

Bimekizumab on-treatment remission as defined by the National Psoriasis Foundation: 1-year results versus ustekinumab and secukinumab in patients with moderate to severe plaque psoriasis (AAD 2026) - "Higher proportions of bimekizumab-treated patients achieved NPF-defined on-treatment remission than ustekinumab-/secukinumab-treated patients from Week28 (earliest timepoint at which remission could be observed) through Year1."

Clinical • Dermatology • Immunology • Psoriasis

Quantifying Delays in Initiation of Biologic Therapy for Pyoderma Gangrenosum (AAD 2026) - "The most prescribed biologics included Ustekinumab (39.3%), Infliximab (37.5%), and Adalimumab (19.6%). Frequent medication denials contribute to treatment delays, increased administrative burden, and patient/provider frustration. While the reasoning and impact of these delays on treatment outcomes for PG requires further study, our findings highlight substantial barriers to biologic access for patients with PG."

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Psoriasis • Pyoderma Gangrenosum

Representation of Race and Ethnicity in Randomized Control Trials of Biologic Therapies for Psoriasis: A Scoping Review (AAD 2026) - " Following Joanna Briggs Institute methodology, we searched MEDLINE (PubMed), Embase (Elsevier), and Cochrane Library in June 2024 for RCTs evaluating efficacy and/or safety of adalimumab, infliximab, etanercept, bimekizumab, ustekinumab, and guselkumab. Black and Hispanic patients remain underrepresented in psoriasis biologic RCTs despite higher disease burden, and demographic reporting is inconsistent, limiting generalizability. Trials documenting race/ethnicity appeared in higher impact, more frequently cited journals. Future biologic trials should prioritize diverse recruitment and standardized demographic reporting to strengthen equity and applicability of findings."

Clinical • Review • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies

Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules. BIOBADADERM Registry. (AAD 2026) - " We analyzed crude incidence rates of overall, serious, recurrent, and infections of special interest in patients treated with etanercept, infliximab, certolizumab, adalimumab, ustekinumab, secukinumab, ixekizumab, brodalumab, bimekizumab, guselkumab, risankizumab, tildrakizumab, apremilast, and dimethyl fumarate. Modern systemic therapies for psoriasis show a favorable infection safety profile in real-world settings. IL-17 inhibitors appear to increase the risk of Candida infections, while some biologics may reduce the incidence of respiratory and viral infections."

Clinical • Candidiasis • Dermatology • Human Papillomavirus Infection • Immunology • Infectious Disease • Nephrology • Novel Coronavirus Disease • Psoriasis • Respiratory Diseases • IL17A

Beyond Trial-and-Error: Mechanism-Guided Use of Biologics in Scalp Psoriasis (AAD 2026) - "Ustekinumab offered modest scalp improvement but lacked dedicated trials. IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) consistently produced the most rapid clearance, with several maintaining high rates of complete response in long-term follow-up. IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) provided excellent durability, with real-world evidence confirming sustained clearance. No scalp-specific outcomes were reported for certolizumab... Biologic selection in scalp psoriasis can move beyond trial-and-error toward mechanism-guided therapy. IL-17 inhibitors are best suited for rapid scalp clearance, while IL-23 inhibitors may optimize long-term durability. These findings support the development of a practical, scalp-specific treatment algorithm to address one of the most visible and burdensome manifestations of psoriasis."

Dermatology • Immunology • Psoriasis • CD8 • IL22 • IL23A

Evidence-Based Biologic Selection for Moderate-to-Severe Psoriasis in Patients with IBD and Heart Failure (AAD 2026) - "These comorbidity-specific algorithms provide practical guidance for biologic selection in psoriasis, advancing care for dual IBD-HF comorbidity, a comparatively understudied population."

Clinical • Cardiovascular • Congestive Heart Failure • Dermatology • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Immunology • Inflammation • Inflammatory Bowel Disease • Psoriasis • IL17A • IL23A